4-(1H-pyrrol-1-yl)phenyl 3,4-dichlorophenethylcarbamate | 1361452-80-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 4-(1H-pyrrol-1-yl)phenyl 3,4-dichlorophenethylcarbamate
• 英文别名: (4-pyrrol-1-ylphenyl) N-[2-(3,4-dichlorophenyl)ethyl]carbamate
• CAS: 1361452-80-3
• 化学式: C₁₉H₁₆Cl₂N₂O₂
• 分子量: 375.254
• InChiKey: AFAUHDXYEFICNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  43.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES
  申请人：Cravatt Benjamin

  公开号：US20130281453A1

  公开（公告）日：2013-10-24

  Serine hydrolases are implicated in malconditions such as cancer, central nervous system disorders, cardiovascular disorders, obesity, and metabolic disorders. Many serine hydrolases expressed in proteomic libraries are of unknown function in vivo. Compounds identified through library versus library screening can be used for treatment of malconditions associated with the specific serine hydrolase KIAA1363 (also known as AADACL1). A library of inhibitors of KIAA1363 was prepared and candidate compounds were identified as a potent inhibitors having submicromolar IC 50 values. An exemplary compound of the invention was shown to be an effective inhibitor of prostate cancer pathogenesis. Other inhibitory compounds of the invention comprising fluorophore groups are shown to be effective in spatial and temporal localization of the serine hydrolase in cells and tissues.

  丝氨酸水解酶与恶性疾病如癌症、中枢神经系统疾病、心血管疾病、肥胖和代谢性疾病有关。在蛋白质组图书馆中表达的许多丝氨酸水解酶在体内的功能尚不清楚。通过图书馆与图书馆的筛选鉴定出的化合物可用于治疗与特定丝氨酸水解酶KIAA1363（也称为AADACL1）相关的疾病。制备了一种KIAA1363抑制剂库，并鉴定出候选化合物作为具有亚微米IC50值的有效抑制剂。本发明的一种示例化合物被证明是前列腺癌发病的有效抑制剂。本发明的其他抑制性化合物包括荧光团，被证明对细胞和组织中的丝氨酸水解酶的时空定位具有有效作用。
• MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES
  申请人：Saulnier Mark G.

  公开号：US20130281657A1

  公开（公告）日：2013-10-24

  The invention provides methods of preparing macrocycles including macrocycle stabilized peptides (MSPs). Macrocycles and MSPs are prepared according to nucleophilic capture of an iminoquinomethide type intermediate generated from a suitably substituted 2-amino-thiazol-5-yl carbinol. The preferred nucleophile may be selected from an electron rich aromatic moiety in the case of macrocycles and, in the case of MSPs, at least one amino acid comprises an electron rich aromatic moiety. In addition, the concept can be extended to other related 5-membered heterocyclic systems in place of the thiazole, such as imidazole or oxazole. The conditions for the generation of the corresponding iminoquinomethide type intermediates may be similar or different than the conditions used for the 2-amino-thiazol-5-yl carbinol.

  本发明提供了制备大环化合物的方法，包括稳定大环化肽（MSPs）。根据适当取代的2-氨基噻唑-5-基甲醇生成的亚胺喹啉甲烷型中间体的亲核捕获，制备大环和MSP。在大环的情况下，首选亲核试剂可以从富电子芳香基团中选择，在MSP的情况下，至少有一种氨基酸包含富电子芳香基团。此外，该概念可以扩展到取代噻唑的其他相关5-成员杂环系统，例如咪唑或噁唑。生成相应的亚胺喹啉甲烷型中间体的条件可能与用于2-氨基噻唑-5-基甲醇的条件相似或不同。
• US9169295B2
  申请人：——

  公开号：US9169295B2

  公开（公告）日：2015-10-27
• US9249128B2
  申请人：——

  公开号：US9249128B2

  公开（公告）日：2016-02-02
• [EN] ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES<br/>[FR] CARBAMATES INHIBITEURS DE SÉRINE HYDROLASES POUR LUTTER CONTRE LE CANCER
  申请人：CRAVATT BENJAMIN

  公开号：WO2012058115A2

  公开（公告）日：2012-05-03

  Serine hydrolases are implicated in malconditions such as cancer, central nervous system disorders, cardiovascular disorders, obesity, and metabolic disorders. Many serine hydrolases expressed in proteomic libraries are of unknown function in vivo. Compounds identified through library versus library screening can be used for treatment of malconditions associated with the specific serine hydrolase KIAA1363 (also known as AADACL1). A library of inhibitors of KIAA1363 was prepared and candidate compounds were identified as a potent inhibitors having submicromolar IC50 values. An exemplary compound of the invention was shown to be an effective inhibitor of prostate cancer pathogenesis. Other inhibitory compounds of the invention comprising fluorophore groups are shown to be effective in spatial and temporal localization of the serine hydrolase in cells and tissues.